Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Looking for Genetic Differences in Never-Smokers who Develop Lung Cancer
Dr West
Author
Howard (Jack) West, MD

Last year I highlighted a research program out of Memorial Sloan-Kettering Cancer Center in NYC that has been trying to identify molecular genetic factors in never-smokers who develop lung cancer that can help provide explanations and even perhaps a better sense of why anyone, including smokers, may be at higher risk for developing lung cancer than others. The study involves just a questionnaire about tobacco and other exposures, and also collecting a couple of vials of blood that can be drawn at your local doctors office and then sent, postage paid, to a lab for genetic analysis.

I saw the investigator leading this effort, Dr. William Pao, at the World Conference on Lung Cancer this past week. He has since been recruited from Memorial Sloan Kettering to Vanderbilt University Medical Center in Nashville, TN, where he's leadinga growing lab-based effort to better understand the genetic underpinnings of lung cancer. The blood collection and genetic analysis is bearing fruit, and he and his colleagues are in the process of writing some of their early findings from this project. They've enrolled many people who found out about this work here, and I've also told my never-smokers about it and encouraged them to consider participating. Who wouldn't want to help understand why some people are at a higher risk for developing lung cancer.

You can find out more information at the website www.vicc.org/neversmokers or by e-mailing neversmokerswithlungcancer@vanderbilt.edu.

vicc-advert

One new development is that the survey is now available online, making it even easier.

Want to know how you can help move the field of cancer research forward? Dr. Pao and his colleagues are at the forefront of this work, and it's never been easier to contribute to work that can have direct effects on identifying those at risk and even potentially finding new treatments.

If you're eligible, please consider participating.


Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on